Annual CFI
$173.80 M
-$78.50 M-31.11%
31 December 2023
Summary:
Edwards Lifesciences annual cash flow from investing activities is currently $173.80 million, with the most recent change of -$78.50 million (-31.11%) on 31 December 2023. During the last 3 years, it has risen by +$704.90 million (+132.72%). EW annual CFI is now -31.11% below its all-time high of $252.30 million, reached on 31 December 2022.EW Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$2.70 B
+$2.58 B+2064.82%
30 September 2024
Summary:
Edwards Lifesciences quarterly cash flow from investing activities is currently $2.70 billion, with the most recent change of +$2.58 billion (+2064.82%) on 30 September 2024. Over the past year, it has increased by +$2.61 billion (+2935.62%). EW quarterly CFI is now at all-time high.EW Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$2.90 B
+$2.61 B+897.84%
30 September 2024
Summary:
Edwards Lifesciences TTM cash flow from investing activities is currently $2.90 billion, with the most recent change of +$2.61 billion (+897.84%) on 30 September 2024. Over the past year, it has increased by +$2.65 billion (+1041.39%). EW TTM CFI is now at all-time high.EW TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EW Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -31.1% | +2935.6% | +1041.4% |
| 3 y3 years | +132.7% | +815.9% | +385.7% |
| 5 y5 years | +126.6% | +10000.0% | +2105.3% |
EW Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -31.1% | +110.1% | at high | +379.7% | at high | +268.6% |
| 5 y | 5 years | -31.1% | +110.1% | at high | +379.7% | at high | +268.6% |
| alltime | all time | -31.1% | +110.1% | at high | +379.7% | at high | +268.6% |
Edwards Lifesciences Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.70 B(+2064.8%) | $2.90 B(+897.8%) |
| June 2024 | - | $124.80 M(+97.8%) | $291.00 M(+23.1%) |
| Mar 2024 | - | $63.10 M(+347.5%) | $236.40 M(+36.0%) |
| Dec 2023 | $173.80 M(-31.1%) | $14.10 M(-84.2%) | $173.80 M(-31.7%) |
| Sept 2023 | - | $89.00 M(+26.8%) | $254.40 M(-804.7%) |
| June 2023 | - | $70.20 M(>+9900.0%) | -$36.10 M(-254.9%) |
| Mar 2023 | - | $500.00 K(-99.5%) | $23.30 M(-90.8%) |
| Dec 2022 | $252.30 M(-114.6%) | $94.70 M(-147.0%) | $252.30 M(-131.2%) |
| Sept 2022 | - | -$201.50 M(-255.5%) | -$808.30 M(-17.9%) |
| June 2022 | - | $129.60 M(-43.5%) | -$984.20 M(-31.8%) |
| Mar 2022 | - | $229.50 M(-123.8%) | -$1.44 B(-16.2%) |
| Dec 2021 | -$1.72 B(+224.3%) | -$965.90 M(+155.9%) | -$1.72 B(+69.5%) |
| Sept 2021 | - | -$377.40 M(+14.5%) | -$1.02 B(+32.8%) |
| June 2021 | - | -$329.50 M(+563.0%) | -$765.40 M(+71.6%) |
| Mar 2021 | - | -$49.70 M(-80.9%) | -$446.10 M(-16.0%) |
| Dec 2020 | -$531.10 M(-10.9%) | -$259.90 M(+105.8%) | -$531.10 M(-25.9%) |
| Sept 2020 | - | -$126.30 M(+1138.2%) | -$716.50 M(+18.8%) |
| June 2020 | - | -$10.20 M(-92.4%) | -$602.90 M(-11.5%) |
| Mar 2020 | - | -$134.70 M(-69.8%) | -$681.00 M(+14.3%) |
| Dec 2019 | -$595.80 M(-876.8%) | -$445.30 M(+3406.3%) | -$595.80 M(+311.5%) |
| Sept 2019 | - | -$12.70 M(-85.6%) | -$144.80 M(-62.5%) |
| June 2019 | - | -$88.30 M(+78.4%) | -$386.30 M(+100.1%) |
| Mar 2019 | - | -$49.50 M(-968.4%) | -$193.10 M(-351.8%) |
| Dec 2018 | $76.70 M(-111.9%) | $5.70 M(-102.2%) | $76.70 M(-36.2%) |
| Sept 2018 | - | -$254.20 M(-342.3%) | $120.30 M(-27.1%) |
| June 2018 | - | $104.90 M(-52.4%) | $165.00 M(-128.5%) |
| Mar 2018 | - | $220.30 M(+346.9%) | -$578.10 M(-10.7%) |
| Dec 2017 | -$647.20 M(+205.7%) | $49.30 M(-123.5%) | -$647.20 M(+5.0%) |
| Sept 2017 | - | -$209.50 M(-67.2%) | -$616.30 M(+53.0%) |
| June 2017 | - | -$638.20 M(-522.1%) | -$402.90 M(+273.7%) |
| Mar 2017 | - | $151.20 M(+88.5%) | -$107.80 M(-49.1%) |
| Dec 2016 | -$211.70 M(-33.0%) | $80.20 M(+1956.4%) | -$211.70 M(-20.0%) |
| Sept 2016 | - | $3.90 M(-101.1%) | -$264.60 M(-40.4%) |
| June 2016 | - | -$343.10 M(-825.4%) | -$444.10 M(+401.8%) |
| Mar 2016 | - | $47.30 M(+73.3%) | -$88.50 M(-72.0%) |
| Dec 2015 | -$316.10 M(-50.1%) | $27.30 M(-115.5%) | -$316.10 M(+36.6%) |
| Sept 2015 | - | -$175.60 M(-1504.8%) | -$231.40 M(+9.9%) |
| June 2015 | - | $12.50 M(-106.9%) | -$210.60 M(-69.6%) |
| Mar 2015 | - | -$180.30 M(-261.0%) | -$693.50 M(+9.6%) |
| Dec 2014 | -$633.00 M(+53.4%) | $112.00 M(-172.4%) | -$633.00 M(-36.2%) |
| Sept 2014 | - | -$154.80 M(-67.1%) | -$991.90 M(+5.1%) |
| June 2014 | - | -$470.40 M(+292.7%) | -$943.60 M(+72.8%) |
| Mar 2014 | - | -$119.80 M(-51.5%) | -$546.20 M(+32.3%) |
| Dec 2013 | -$412.70 M(+423.7%) | -$246.90 M(+131.8%) | -$412.70 M(+198.2%) |
| Sept 2013 | - | -$106.50 M(+45.9%) | -$138.40 M(-15.5%) |
| June 2013 | - | -$73.00 M(-632.8%) | -$163.80 M(+22.7%) |
| Mar 2013 | - | $13.70 M(-50.0%) | -$133.50 M(+69.4%) |
| Dec 2012 | -$78.80 M | $27.40 M(-120.8%) | -$78.80 M(-63.3%) |
| Sept 2012 | - | -$131.90 M(+208.9%) | -$214.50 M(+685.7%) |
| June 2012 | - | -$42.70 M(-162.4%) | -$27.30 M(-84.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $68.40 M(-163.2%) | -$180.00 M(-55.7%) |
| Dec 2011 | -$406.50 M(+561.0%) | -$108.30 M(-295.8%) | -$406.50 M(+26.5%) |
| Sept 2011 | - | $55.30 M(-128.3%) | -$321.30 M(-18.0%) |
| June 2011 | - | -$195.40 M(+23.6%) | -$391.80 M(+83.9%) |
| Mar 2011 | - | -$158.10 M(+584.4%) | -$213.10 M(+246.5%) |
| Dec 2010 | -$61.50 M(-253.4%) | -$23.10 M(+52.0%) | -$61.50 M(+13.3%) |
| Sept 2010 | - | -$15.20 M(-9.0%) | -$54.30 M(-482.4%) |
| June 2010 | - | -$16.70 M(+156.9%) | $14.20 M(-12.9%) |
| Mar 2010 | - | -$6.50 M(-59.1%) | $16.30 M(-59.4%) |
| Dec 2009 | $40.10 M(-31.8%) | -$15.90 M(-129.8%) | $40.10 M(+2.3%) |
| Sept 2009 | - | $53.30 M(-465.1%) | $39.20 M(-340.5%) |
| June 2009 | - | -$14.60 M(-184.4%) | -$16.30 M(+139.7%) |
| Mar 2009 | - | $17.30 M(-203.0%) | -$6.80 M(-111.6%) |
| Dec 2008 | $58.80 M(-140.7%) | -$16.80 M(+663.6%) | $58.80 M(-443.9%) |
| Sept 2008 | - | -$2.20 M(-56.9%) | -$17.10 M(-41.6%) |
| June 2008 | - | -$5.10 M(-106.2%) | -$29.30 M(-26.8%) |
| Mar 2008 | - | $82.90 M(-189.4%) | -$40.00 M(-72.3%) |
| Dec 2007 | -$144.50 M(+304.8%) | -$92.70 M(+543.8%) | -$144.50 M(+144.1%) |
| Sept 2007 | - | -$14.40 M(-8.9%) | -$59.20 M(-2.1%) |
| June 2007 | - | -$15.80 M(-26.9%) | -$60.50 M(+15.9%) |
| Mar 2007 | - | -$21.60 M(+191.9%) | -$52.20 M(+46.2%) |
| Dec 2006 | -$35.70 M(+31.3%) | -$7.40 M(-52.9%) | -$35.70 M(-3.8%) |
| Sept 2006 | - | -$15.70 M(+109.3%) | -$37.10 M(+12.4%) |
| June 2006 | - | -$7.50 M(+47.1%) | -$33.00 M(-6.0%) |
| Mar 2006 | - | -$5.10 M(-42.0%) | -$35.10 M(+29.0%) |
| Dec 2005 | -$27.20 M(-84.6%) | -$8.80 M(-24.1%) | -$27.20 M(-26.3%) |
| Sept 2005 | - | -$11.60 M(+20.8%) | -$36.90 M(-16.3%) |
| June 2005 | - | -$9.60 M(-442.9%) | -$44.10 M(+5.3%) |
| Mar 2005 | - | $2.80 M(-115.1%) | -$41.90 M(-76.3%) |
| Dec 2004 | -$177.10 M(+130.3%) | -$18.50 M(-1.6%) | -$177.10 M(-8.0%) |
| Sept 2004 | - | -$18.80 M(+154.1%) | -$192.50 M(+3.4%) |
| June 2004 | - | -$7.40 M(-94.4%) | -$186.10 M(+0.5%) |
| Mar 2004 | - | -$132.40 M(+290.6%) | -$185.10 M(+140.7%) |
| Dec 2003 | -$76.90 M(+12.6%) | -$33.90 M(+173.4%) | -$76.90 M(-6.9%) |
| Sept 2003 | - | -$12.40 M(+93.8%) | -$82.60 M(+2.4%) |
| June 2003 | - | -$6.40 M(-73.6%) | -$80.70 M(-5.1%) |
| Mar 2003 | - | -$24.20 M(-38.9%) | -$85.00 M(+24.5%) |
| Dec 2002 | -$68.30 M(+1607.5%) | -$39.60 M(+277.1%) | -$68.30 M(+68.2%) |
| Sept 2002 | - | -$10.50 M(-1.9%) | -$40.60 M(-9.6%) |
| June 2002 | - | -$10.70 M(+42.7%) | -$44.90 M(-2463.2%) |
| Mar 2002 | - | -$7.50 M(-37.0%) | $1.90 M(-147.5%) |
| Dec 2001 | -$4.00 M(-94.7%) | -$11.90 M(-19.6%) | -$4.00 M(+48.1%) |
| Sept 2001 | - | -$14.80 M(-141.0%) | -$2.70 M(-131.0%) |
| June 2001 | - | $36.10 M(-369.4%) | $8.70 M(-114.2%) |
| Mar 2001 | - | -$13.40 M(+26.4%) | -$61.40 M(-18.1%) |
| Dec 2000 | -$75.00 M(+53.1%) | -$10.60 M(+211.8%) | -$75.00 M(+16.5%) |
| Sept 2000 | - | -$3.40 M(-90.0%) | -$64.40 M(+5.6%) |
| June 2000 | - | -$34.00 M(+25.9%) | -$61.00 M(+125.9%) |
| Mar 2000 | - | -$27.00 M | -$27.00 M |
| Dec 1999 | -$49.00 M | - | - |
FAQ
- What is Edwards Lifesciences annual cash flow from investing activities?
- What is the all time high annual CFI for Edwards Lifesciences?
- What is Edwards Lifesciences annual CFI year-on-year change?
- What is Edwards Lifesciences quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Edwards Lifesciences?
- What is Edwards Lifesciences quarterly CFI year-on-year change?
- What is Edwards Lifesciences TTM cash flow from investing activities?
- What is the all time high TTM CFI for Edwards Lifesciences?
- What is Edwards Lifesciences TTM CFI year-on-year change?
What is Edwards Lifesciences annual cash flow from investing activities?
The current annual CFI of EW is $173.80 M
What is the all time high annual CFI for Edwards Lifesciences?
Edwards Lifesciences all-time high annual cash flow from investing activities is $252.30 M
What is Edwards Lifesciences annual CFI year-on-year change?
Over the past year, EW annual cash flow from investing activities has changed by -$78.50 M (-31.11%)
What is Edwards Lifesciences quarterly cash flow from investing activities?
The current quarterly CFI of EW is $2.70 B
What is the all time high quarterly CFI for Edwards Lifesciences?
Edwards Lifesciences all-time high quarterly cash flow from investing activities is $2.70 B
What is Edwards Lifesciences quarterly CFI year-on-year change?
Over the past year, EW quarterly cash flow from investing activities has changed by +$2.61 B (+2935.62%)
What is Edwards Lifesciences TTM cash flow from investing activities?
The current TTM CFI of EW is $2.90 B
What is the all time high TTM CFI for Edwards Lifesciences?
Edwards Lifesciences all-time high TTM cash flow from investing activities is $2.90 B
What is Edwards Lifesciences TTM CFI year-on-year change?
Over the past year, EW TTM cash flow from investing activities has changed by +$2.65 B (+1041.39%)